2.57 USD
▲+0.05+2.80%
盘后 2.40 -4.12%
2026-08-03
市值
$299.56M
市盈率
—
EPS
-1.09
股息率
—
52 周区间
0.91 – 3.23
成交量
6.44M
Beta
2.52
目标价
5.41
52W 低 0.9152W 高 3.23
价格走势
公司简介
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tum...